Oscar Health, Inc. (OSCR) concluded the recent trading session at $14.45, signifying a +1.76% move from its prior day's close.
In the most recent trading session, Oscar Health, Inc. (OSCR) closed at $14.2, indicating a -10.52% shift from the previous trading day.
Key Points in This Article: Oscar Health's (OSCR) stock surged in June 2025 due to strong Q1 earnings but crashed after Centene's guidance withdrawal and analyst downgrades.
Oscar Health, Inc. (OSCR) closed at $15.35 in the latest trading session, marking a +2.88% move from the prior day.
Oscar Health, Inc. (OSCR) closed at $15.53 in the latest trading session, marking a -3.42% move from the prior day.
In the latest trading session, Oscar Health, Inc. (OSCR) closed at $16.55, marking a -1.55% move from the previous day.
Centene's $1.8B ACA risk shock triggered a ~15-20% drop in Oscar's stock but didn't alter Q1 fundamentals. Oscar posted 42% revenue growth, expanding to 2 million members with a record-low 15.8% SG&A expense ratio. Barclays' downgrade highlights policy risk, projecting over 100bps MLR pressure and aggressive EPS cuts if subsidies expire.
On July 2nd, the health insurance sector underwent a notable decline following Centene (NYSE:CNC)'s retraction of its financial outlook, citing rising costs. Refer to – Centene: Is The Recent Decline In CNC Stock Justified?
Oscar Health, Inc. (OSCR) concluded the recent trading session at $16.62, signifying a -18.73% move from its prior day's close.
Oscar Health, Inc. (OSCR) closed the most recent trading day at $20.45, moving 4.62% from the previous trading session.
Oscar generated $328.8 million in Q1 adjusted EBITDA with a 9.8% operating margin, up 110 bps year-over-year. SG&A ratio fell to 15.8%, driven by 40% fixed-cost leverage and 15% tech-driven efficiencies like 98% auto-claims processing. A 5-year DCF with 30% FCF growth and a 5x terminal multiple supports a $61/share fair value, over 3x upside.
Oscar Health's tech-driven flywheel is shrinking costs, boosting retention, and driving rapid membership growth, validated by 42% revenue growth and record profitability in Q1 2025. Platform revenue from +Oscar and data licensing is compounding faster than insurance premiums, creating a high-margin, SaaS-like earnings stream that legacy insurers can't match. Favorable policy trends and employer adoption of ICHRAs funnel incremental lives to Oscar at low acquisition cost, while Oscar's consumer-centric UX and provider partnerships deepen its moat.